COA At-a-Glance
Evidence of cognitive interviewing of draft instrument in target patient population
Evidence of internal consistency
Evidence of test-retest or inter-rater reliability
Evidence of concurrent validity
Evidence of known-groups validity
Evidence of ability to detect change over time
Evidence of responder thresholds
Inclusion of the COA in product labelling
- Overview
- Content Validity
- Reliability
- Validity
- Ability to Detect Change
- Responder Thresholds
- Reference(s) of development / validation
- Other references
- Inclusion of the COA in product labelling
- Existence of Scoring / Interpretation / User Manual
- Original language and translations
- References of translations
- Authors and contact information
- Condition of use: copyright
- Website
- Review copy
Overview
Instrument Name: Vineland Adaptive Behaviour Scales II - Survey Interview form
Abbreviation: Vineland II - Survey Interview form
Description of Tool:
The Vineland Adaptive Behaviour Scales II - Survey Interview form is an ObsRO developed to assess personal and social skills used by an individual or child aged 0-90 years in daily situations. Especially suitable for assessing those with mental retardation or who have difficulty performing in testing situations.
Other Related Tools (if applicable):
Vineland III Comprehensive Interview Form - Vineland Adaptive Behaviour Scales - Third Edition Comprehensive Interview Form
Vineland III Domain-Level Interview Form - Vineland Adaptive Behaviour Scales - Third Edition Domain-Level Interview Form
Vineland III Comprehensive Parent/Caregiver Form - Vineland Adaptive Behaviour Scales - Third Edition Comprehensive Parent/Caregiver Form
Vineland III Domain-Level Parent/Caregiver Form - Vineland Adaptive Behaviour Scales - Third Edition Domain-Level Parent/Caregiver Form
Vineland III Comprehensive Teacher Form - Vineland Adaptive Behaviour Scales - Third Edition Comprehensive Teacher Form
Vineland III Domain-Level Teacher Form - Vineland Adaptive Behaviour Scales - Third Edition Domain-Level Teacher Form
Vineland Adaptive Behavior Scales - Third Edition Maladaptive Behavior Domain Comprehensive Interview Form
Vineland Adaptive Behavior Scales – Third Edition Maladaptive Behavior Domain Comprehensive Parent/Caregiver Form
Vineland Adaptive Behavior Scales – Third Edition Maladaptive Behavior Domain Domain-Level Interview Form
Vineland Adaptive Behavior Scales – Third Edition Maladaptive Behavior Domain Domain-Level Parent/Caregiver Form
Vineland II - Expanded Interview form - Vineland Adaptive Behaviour Scales II - Expanded Interview form
Vineland II - Parent/Caregiver form - Vineland Adaptive Behaviour Scales II - Parent/Caregiver form
Vineland II - Teacher Rating form - Vineland Adaptive Behaviour Scales II - Teacher Rating form
Minimum Qualification Required by COA Administrator: MA or BA
Comment:
Published in 1984, revised in 2005
Expanded Interview, Parent/Caregiver and Teacher Rating forms were also developed
Year: 2005
Objective of Development:
To assess personal and social skills used by an individual or child in daily situations. Especially suitable for assessing those with mental retardation or who have difficulty performing in testing situations.
Population of Development: Age range (therapeutic indication):
0-90 years (Generic for Psychiatry Psychology)
Pediatric Population(s) in which COA has been used:
Vineland II: Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases; Mental Disorders; Neoplasms; Nutritional and Metabolic Diseases; Male Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Cardiovascular Diseases; Endocrine System Diseases; Wounds and Injuries; Skin and Connective Tissue Diseases; Hemic and Lymphatic Diseases; Virus Diseases; Digestive System Diseases; Musculoskeletal Diseases; Otorhinolaryngologic Diseases
COA type:
Number of Items 433 items
Mode of Administration:
Data Collection Mode:
Time for Completion: 20-60 min
Response Scales: 3-point Likert/Likert-type Scale ranging from 0 "Never" to 2 "Usually"
Summary of Scoring:
Available Scores:
- Scores by domains
Weighting:
- No
Score Direction:
No information
Content Validity
Evidence of Literature Review: None identified
Evidence of Instrument Review: None identified
Evidence of Clinical or Expert Input: None identified
Evidence of concept elicitation in target patient population: None identified
Evidence of a Saturation Grid: None identified
Evidence for Selection of Data Collection Method: None identified
Recall/Observation Period:
Evidence for Selection of Reponse Options: None identified
Evidence of cognitive interviewing of draft instrument in target patient population: None identified
Evidence of Preliminary Scoring of Items and Domains: None identified
Evidence related to respondent and administrator burden: None identified
Evidence of a Conceptual Framework: None identified
Evidence of an item-tracking matrix: None identified
Evidence related to item selection: None identified
Evidence of re-testing the final version: None identified
Reliability
Internal consistency (Cronbach's alpha): None identified
Evidence of internal consistency:
Test-retest Reliability (ICC):
None identified
Inter-rater/ inter-interviewer reliability (kappa):
None identified
Evidence of test-retest or inter-rater reliability: None identified
Validity
Concurrent validity (convergent, divergent):
None identified
Known-group validity:
Ekstrom AB (2009)
Measure/Groups of patients: Correlation between VABS-II without motor domain and Full Scale Intelligence Quotient (FSIQ) determined with Griffiths Developmental Scale, Wechsler Primary and Preschool Scale of Intelligence-Revised, Wechsler Intelligence Scale for Children or Wechsler Adult Intelligence Scale in patients with myotonic dystrophy type 1 (DM1) classified into categories: congenital DM1 (= 19), mild congenital DMA (n= 18) and childhood DM1 (n= 18)
A priori hypotheses: Not stated
Were hypotheses confirmed: Not applicable
Results: Spearman's coefficient correlation
- Significant (p< 0.01) correlation was found between FSIQ and VABS-II in the mild congenital DM1 group: r= 0.95
- Significant (p< 0.01) correlation was found between FSIQ and VABS-II in the childhood DM1: r= 0.92
Population/Disease: Patients with DM1; n= 55
Severe congenital DM1 (n= 19, mean age year:month (SD)= 10:7 (6:1)
Mild congenital DM1 (n= 18, mean age year: month (SD)= 11:11 (4:5)
Childhood DM1 (n= 18, mean age year: month (SD)= 13:8 (4:2)
Evidence of Translatability Assessment: None identified
Evidence related to missing data: No information
Evidence for Selection of Recall Period: None identified
Evidence of Administration Instructions and Training Provided: Yes
Evidence of concurrent validity: None identified
Evidence of known-groups validity: Yes
Evidence of ability to detect change over time: None identified
Ability to Detect Change
Ability to detect change (Responsiveness):
None identified
Responder Thresholds
Responder Thresholds:
None identified
Evidence of responder thresholds: None identified
Reference(s) of development / validation
Pearson’s Clinical Assessment group. Vineland Adaptive Behavior Scales | Third Edition [Internet].Bloomington, USA: Pearson; Consulted on March 23rd. Available from: https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Behavior/Adaptive/Vineland-Adaptive-Behavior-Scales-%7C-Third-Edition/p/100001622.html?tab=resources
Other references:
EKSTRÖM, ANNE‐BERIT, et al. "Cognition and adaptive skills in myotonic dystrophy type 1: a study of 55 individuals with congenital and childhood forms." Developmental Medicine & Child Neurology 51.12 (2009): 982-990. (https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-8749.2009.03300.x)
Fisch, Gene S., et al. "The course of cognitive‐behavioral development in children with the FMR1 mutation, Williams–Beuren syndrome, and neurofibromatosis type 1: The effect of gender." American Journal of Medical Genetics Part A 152.6 (2010): 1498-1509. (https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.33412)
Truxal, K. V., et al. "A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design." Molecular genetics and metabolism 119.3 (2016): 239-248.
Bennett, Jeffrey A., et al. "Investigating autism-related symptoms in children with Prader-Willi syndrome: A case study." International journal of molecular sciences 18.3 (2017): 517. (https://www.mdpi.com/1422-0067/18/3/517)
Other references
Farmer C, Adedipe D, Bal VH, Chlebowski C, Thurm A. Concordance of the Vineland Adaptive Behavior Scales, second and third editions. J Intellect Disabil Res. 2020 Jan;64(1):18-26. doi: 10.1111/jir.12691. Epub 2019 Oct 28. PMID: 31657503; PMCID: PMC6941197.
Inclusion of the COA in product labelling
None identified
Existence of Scoring / Interpretation / User Manual
Original language and translations
Original language: English
Translations:
*Cebuano for the Philippines
*Danish for Denmark
*Dutch for Belgium (Flemish)
*Dutch for the Netherlands
*English for Australia
*English for Canada
* English for South Africa
*English for the UK
*French for Belgium
*French for Canada
*German for Germany
*Greek for Greece
*Hebrew for Israel
*Japanese for Japan
*Korean for South Korea
*Norwegian for Norway
*Polish for Poland
*Portuguese for Portugal
*Spanish for Argentina
*Spanish for Colombia
*Spanish for Mexico
*Spanish for the USA
*Tagalog for the Philippines
*Turkish for Turkey
References of translations
None identified
Condition of use: copyright
*With fees for academic/non profit research
*With fees for commercial/pharmaceutical companies
*With the signature of a contract/agreement
*Other: Please contact Pearson Assessment, Inc.
Website
https://www.pearsonassessments.com/
Review copy
Please contact Pearson Assessment, Inc